GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Sarepta Therapeutics Inc (SRPT) [hlAlert]

Rating:
Outperform
SRPT
up 153.00 %

Sarepta Therapeutics Inc (SRPT) upgraded to Outperform with price target $20 by Robert W. Baird

Posted on: Wednesday,  May 6, 2015  8:25 AM ET by Robert W. Baird

Robert W. Baird rated Outperform Sarepta Therapeutics Inc (NASDAQ: SRPT) on 05/06/2015, when the stock price was $14.32.
Since then, Sarepta Therapeutics Inc has gained 153.00% as of 01/19/2016's recent price of $36.23.
If you would have followed this Robert W. Baird's recommendation on SRPT, you would have gained 153% of your investment in 258 days.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/6/2015 8:25 AM Buy
None
14.32 20.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/28/2014 8:25 AM Hold
None
15.86 21.00
4/4/2013 8:25 AM Buy
None
35.82 63.00
4/3/2013 5:25 PM Buy
None
63.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy